title: [Intensive combined therapy for high-risk ALL patients].
abstract: In the risk-adapted multicenter trial (02/84) for adult ALL the effectiveness of a consolidation therapy consisting of VM26 and Ara-C for high-risk patients was tested. Out of a total of 442 patients in the study, 79.2% achieved a complete remission. For the 182 high-risk patients the median remission duration is 17 months and the probability of being in continuous complete remission (CCR) is 34%. Improved results were found for elderly ALL patients between 35 and 65 years of age, whose median remission duration and CCR rate are 19 months and 40% respectively, compared to 15 months and 26% in the former study 01/81. The consolidation therapy has apparently also benefited patients with the immunological subtype c-ALL, for whom the CCR rate at 3 years is 53% in comparison to the previous value of 34%.
authors.affiliation: Univ. Klinik, Frankfurt.
authors.forename: D
authors.initials: D
authors.lastname: Hoelzer
authors.forename: E
authors.initials: E
authors.lastname: Thiel
authors.forename: H
authors.initials: H
authors.lastname: Löffler
authors.forename: T
authors.initials: T
authors.lastname: Büchner
authors.forename: A
authors.initials: A
authors.lastname: Ganser
authors.forename: G
authors.initials: G
authors.lastname: Heil
authors.forename: E
authors.initials: E
authors.lastname: Kurrle
authors.forename: H
authors.initials: H
authors.lastname: Heimpel
authors.forename: P
authors.initials: P
authors.lastname: Koch
authors.forename: T
authors.initials: T
authors.lastname: Lipp
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003561:Cytarabine / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007945:Leukemia, Lymphoid / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012307:Risk Factors
chemical_list: D003561:Cytarabine; D005047:Etoposide
vernacular_title: Intensivierte Konsolidierungstherapie für ALL-Hochrisikopatienten.